The abstract is read at the publisher; the summary is JClub's.
In TopoI-induced systemic sclerosis mice, murinised efgartigimod FcRn blockade ameliorates dermal and pulmonary fibrosis comparably to nintedanib.
- Why it matters: Autoantibodies drive inflammation and scarring in SSc, but therapies that reduce pathogenic IgG while dampening immune-fibrotic programs are needed.
- What they did: TopoI mice received prophylactic or therapeutic mEfgartigimod or an FcRn-blocking IgG1 Fc fragment, with fibrosis assessed by biochemical and histological readouts plus Olink, RNA-Seq, and imaging mass cytometry.
- The result: FcRn blockade downregulated inflammatory/autoimmune/fibrotic pathways, reduced myofibroblasts and immune-cell accumulation, lowered circulating Il1β and chemokines, and increased antifibrotic mediators like Fgf21 and soluble Pd-l2.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.